Melanoma-associated leukoderma - immunology in black and white?

Pigment Cell and Melanoma Research

Volumn 26, Issue 6, 2013, Pages 796-804

  Naveh, Hadas Prag ^a,b   Rao, Uma N M ^b   Butterfield, Lisa H ^a,b,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Immunity; Leukoderma; Melanocyte; Melanoma; Nevus; Vitiligo

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MELAN A; MELANIN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HALO NEVUS; HUMAN; KERATINOCYTE; LEUKODERMA; MELANOCYTE; MELANOMA; MELANOMA ASSOCIATED LEUKODERMA; MELANOMA CELL; MELANOSOME; PATHOGENESIS; REVIEW; T LYMPHOCYTE;

IMMUNITY; LEUKODERMA; MELANOCYTE; MELANOMA; NEVUS; VITILIGO;

HUMANS; HYPOPIGMENTATION; MELANOCYTES; MELANOMA; NEVUS; REMISSION INDUCTION; VITILIGO;

EID: 84886307040     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12161     Document Type: Review

References (69)

1. American Cancer Society. (2013). American Cancer Society: Cancer Facts & Figures 2013.
2. Aouthmany, M., Weinstein, M., Zirwas, M.J., and Brodell, R.T. (2012). The natural history of halo nevi: a retrospective case series. J. Am. Acad. Dermatol. 67, 582-586.
3. Bandarchi, B., Jabbari, C.A., Vedadi, A., and Navab, R. (2013). Molecular biology of normal melanocytes and melanoma cells. J. Clin. Pathol. 66, 644-648.
4. Barrow, C., Browning, J., MacGregor, D., Davis, I.D., Sturrock, S., Jungbluth, A.A., and Cebon, J. (2006). Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12, 764-771.
5. Becker, J.C., Guldberg, P., Zeuthen, J., Brocker, E.B., and Straten, P.T. (1999). Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J. Invest. Dermatol. 113, 1033-1038.
6. Blessing, K., and McLaren, K.M. (1992). Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 20, 315-322.
7. Boasberg, P.D., Hoon, D.S., Piro, L.D., Martin, M.A., Fujimoto, A., Kristedja, T.S., Bhachu, S., Ye, X., Deck, R.R., and O'Day, S.J. (2006). Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J. Invest. Dermatol. 126, 2658-2663.
8. Bolognia, J.L., Jorizzo, J.L., and Rapini, R.P. (2009). Dermatologia (Bolognia, Dermatology). (London: Mosby).
9. Bories, N., Dalle, S., Debarbieux, S., Balme, B., Ronger-Savle, S., and Thomas, L. (2008). Dermoscopy of fully regressive cutaneous melanoma. Br. J. Dermatol. 158, 1224-1229.
10. Brahmer, J.R., Tykodi, S.S., Chow, L.Q. et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465.
11. Bustamante, J., Bredeston, L., Malanga, G., and Mordoh, J. (1993). Role of melanin as a scavenger of active oxygen species. Pigment Cell Res. 6, 348-353.
12. Butterfield, L.H., Ribas, A., Dissette, V.B. et al. (2003). Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9, 998-1008.
13. Butterfield, L.H., Comin-Anduix, B., Vujanovic, L. et al. (2008). Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J. Immunother. 31, 294-309.
14. Bystryn, J.C., Rigel, D., Friedman, R.J., and Kopf, A. (1987). Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dermatol. 123, 1053-1055.
15. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 364, 2507-2516.
16. De Maziere, A.M., Muehlethaler, K., van Donselaar, E., Salvi, S., Davoust, J., Cerottini, J.C., Levy, F., Slot, J.W., and Rimoldi, D. (2002). The melanocytic protein Melan-A/MART-1 has a subcellular localization distinct from typical melanosomal proteins. Traffic 3, 678-693.
17. Disis, M.L. (2011). Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol. Immunother. 60, 433-442.
18. Du, J., Miller, A.J., Widlund, H.R., Horstmann, M.A., Ramaswamy, S., and Fisher, D.E. (2003). MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am. J. Pathol. 163, 333-343.
19. Dudley, M.E., Wunderlich, J.R., Robbins, P.F. et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854.
20. Ezzedine, K., Lim, H.W., Suzuki, T. et al. (2012). Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res., 25, E1-E13.
21. Fontaine, D., Parkhill, W., Greer, W., and Walsh, N. (2003). Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? Am. J. Dermatopathol. 25, 371-376.
22. van Geel, N., Speeckaert, R., Lambert, J., Mollet, I., de Keyser, S., de Schepper, S., and Brochez, L. (2012). Halo naevi with associated vitiligo-like depigmentations: pathogenetic hypothesis. J. Eur. Acad. Dermatol. Venereol. 26, 755-761.
23. Goff, S.L., Smith, F.O., Klapper, J.A., Sherry, R., Wunderlich, J.R., Steinberg, S.M., White, D., Rosenberg, S.A., Dudley, M.E., and Yang, J.C. (2010). Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J. Immunother. 33, 840-847.
24. Gogas, H., Ioannovich, J., Dafni, U. et al. (2006). Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709-718.
25. Guitart, J., Lowe, L., Piepkorn, M., Prieto, V.G., Rabkin, M.S., Ronan, S.G., Shea, C.R., Tron, V.A., White, W., and Barnhill, R.L. (2002). Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch. Dermatol. 138, 603-608.
26. Haluska, F., Linette, G., Jonash, S. et al. (2000). Immunologic gene therapy of melanoma: Phase I study of therapy with dendritic cells transduced with recombinant adenoviruses encoding melanoma antigens (Abstract 1777). Proc. Am. Soc. Clin. Oncol. (Abstract) 19, 453a.
27. Hann, S.K., and Nordlund, J.J. (2000). Vitiligo: A Monograph on the Basic and Clinical Science. (Malden, MA: Wiley, John & Sons, Inc).
28. Hartmann, A., Bedenk, C., Keikavoussi, P., Becker, J.C., Hamm, H., and Brocker, E.B. (2008). Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J. Dtsch. Dermatol. Ges. 6, 1053-1059.
29. Hemon, P., Jean-Louis, F., Ramgolam, K. et al. (2011). MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J. Immunol. 186, 5173-5183.
30. High, W.A., Stewart, D., Wilbers, C.R., Cockerell, C.J., Hoang, M.P., and Fitzpatrick, J.E. (2005). Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. J. Am. Acad. Dermatol. 53, 89-100.
31. Hoashi, T., Watabe, H., Muller, J., Yamaguchi, Y., Vieira, W.D., and Hearing, V.J. (2005). MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J. Biol. Chem. 280, 14006-14016.
32. Hoashi, T., Tamaki, K., and Hearing, V.J. (2010). The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. FASEB J. 24, 916-930.
33. Hodgkinson, C.A., Moore, K.J., Nakayama, A., Steingrimsson, E., Copeland, N.G., Jenkins, N.A., and Arnheiter, H. (1993). Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74, 395-404.
34. Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
35. Irvine, D.J., Purbhoo, M.A., Krogsgaard, M., and Davis, M.M. (2002). Direct observation of ligand recognition by T cells. Nature 419, 845-849.
36. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 88-93.
37. Kaur, C., Thomas, R.J., Desai, N., Green, M.A., Lovell, D., Powell, B.W., and Cook, M.G. (2008). The correlation of regression in primary melanoma with sentinel lymph node status. J. Clin. Pathol. 61, 297-300.
38. Kolm, I., di Stefani, A., Hofmann-Wellenhof, R., Fink-Puches, R., Wolf, I.H., Richtig, E., Smolle, J., Kerl, H., Soyer, H.P., and Zalaudek, I. (2006). Dermoscopy patterns of halo nevi. Arch. Dermatol. 142, 1627-1632.
39. Lewis, M.G., and Copeman, P.W. (1972). Halo naevus-a frustrated malignant melanoma. Br. Med. J. 2, 47-48.
40. Mellman, I., Coukos, G., and Dranoff, G. (2011). Cancer immunotherapy comes of age. Nature 480, 480-489.
41. Menzies, S.W., and McCarthy, W.H. (1997). Complete regression of primary cutaneous malignant melanoma. Arch. Surg. 132, 553-556.
42. Moretti, S., Spallanzani, A., Pinzi, C., Prignano, F., and Fabbri, P. (2007). Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment? J. Cutan. Pathol. 34, 301-308.
43. Morris, K.T., Busam, K.J., Bero, S., Patel, A., and Brady, M.S. (2008). Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann. Surg. Oncol. 15, 316-322.
44. Musette, P., Bachelez, H., Flageul, B., Delarbre, C., Kourilsky, P., Dubertret, L., and Gachelin, G. (1999). Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. J. Immunol. 162, 1789-1794.
45. Nazarian, R.M., Prieto, V.G., Elder, D.E., and Duncan, L.M. (2010). Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J. Cutan. Pathol. 37(Suppl 1), 41-47.
46. Nordlund, J.J., Kirkwood, J.M., Forget, B.M., Milton, G., Albert, D.M., and Lerner, A.B. (1983). Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Dermatol. 9, 689-696.
47. Olah, J., Gyulai, R., Korom, I., Varga, E., and Dobozy, A. (2003). Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br. J. Dermatol. 149, 662-663.
48. Overwijk, W.W., and Restifo, N.P. (2000). Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit. Rev. Immunol. 20, 433-450.
49. + T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology 219, 250-258.
50. Quaglino, P., Marenco, F., Osella-Abate, S., Cappello, N., Ortoncelli, M., Salomone, B., Fierro, M.T., Savoia, P., and Bernengo, M.G. (2010). Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann. Oncol. 21, 409-414.
51. Ram, M., and Shoenfeld, Y. (2007). Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann. N. Y. Acad. Sci. 1110, 410-425.
52. Rao, U.N., Lee, S.J., Luo, W., Mihm, M.C. Jr, and Kirkwood, J.M. (2010). Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am. J. Clin. Pathol. 133, 646-653.
53. Requena, C., Botella-Estrada, R., Traves, V., Nagore, E., Almenar, S., and Guillen, C. (2009). Problems in defining melanoma regression and prognostic implication. Actas Dermosifiliogr 100, 759-766.
54. Ribas, A., Glaspy, J.A., Lee, Y. et al. (2004). Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J. Immunother. 27, 354-367.
55. Rimoldi, D., Muehlethaler, K., Salvi, S., Valmori, D., Romero, P., Cerottini, J.C., and Levy, F. (2001). Subcellular localization of the melanoma-associated protein Melan-AMART-1 influences the processing of its HLA-A2-restricted epitope. J. Biol. Chem. 276, 43189-43196.
56. Rongioletti, F., Cecchi, F., and Rebora, A. (2011). Halo phenomenon in melanocytic nevi (Sutton's nevi). Does the diameter matter? J. Eur. Acad. Dermatol. Venereol. 25, 1231-1232.
57. Rosenberg, S.A., and White, D.E. (1996). Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19, 81-84.
58. Rubegni, P., Nami, N., Risulo, M., Tataranno, D., and Fimiani, M. (2009). Melanoma with halo. Clin. Exp. Dermatol. 34, 749-750.
59. Schallreuter, K.U., Levenig, C., and Berger, J. (1991). Vitiligo and cutaneous melanoma. A case study. Dermatologica 183, 239-245.
60. Sosman, J.A., Kim, K.B., Schuchter, L. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
61. Speeckaert, R., van Geel, N., Luiten, R.M., van Gele, M., Speeckaert, M., Lambert, J., Vermaelen, K., Tjin, E.P., and Brochez, L. (2011). Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. Anticancer Res. 31, 3697-3703.
62. Teulings, H.E., Tjin, E.P., Willemsen, K.J., Krebbers, G., van Noesel, C.J., Kemp, E.H., Nieuweboer-Krobotova, L., van der Veen, J.P., and Luiten, R.M. (2013). Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis. Br. J. Dermatol. 168, 733-738.
63. Theos, A.C., Truschel, S.T., Raposo, G., and Marks, M.S. (2005). The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res. 18, 322-336.
64. Topalian, S.L., Hodi, F.S., Brahmer, J.R. et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
65. Tsao, H., Millman, P., Linette, G.P., Hodi, F.S., Sober, A.J., Goldberg, M.A., and Haluska, F.G. (2002). Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch. Dermatol. 138, 799-802.
66. Wolchok, J.D., Kluger, H., Callahan, M.K. et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133.
67. Yang, Y., Lin, X., Fu, W., Luo, X., and Kang, K. (2010). An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clin. Exp. Dermatol. 35, 706-710.
68. Zeff, R.A., Freitag, A., Grin, C.M., and Grant-Kels, J.M. (1997). The immune response in halo nevi. J. Am. Acad. Dermatol. 37, 620-624.
69. Zippelius, A., Pittet, M.J., Batard, P. et al. (2002). Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195, 485-494.